epirubicin Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 2 (2)

Interventional (2)

Chinese Academy of Medical Sciences (1)
Henan Cancer Hospital (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/hadcancer

I am/have/hadbreast cancer

I am/have/hadadjuvant chemotherapy

I am/have/hadadenocarcinoma

I am/have/hadtriple negative breast cancer

I am/have/hadadenocarcinoma of the breast

I am/have/hadresidual tumor

I am/have/hadHER2

I am/have/hadbreast surgery

I am/have/hadrenal disease

I am/have/hadlymphoma

I am/have/hadtumor excision

I am/have/hadmarginal zone lymphoma

I am/have/hadtriple negative breast neoplasms

I am/have/hadmalt

added new label for I am/have/had

more

I am looking for

I am looking forepirubicin

I am looking forcyclophosphamide

I am looking foradjuvant

I am looking fortaxane

I am looking forbortezomib

I am looking forprednisone

I am looking forimmunomodulators

I am looking forrituximab

added new label for I am looking for

more

Advanced Filters

Loading...

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 2
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Hematology
Recruiting

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

prednisone

bortezomib

epirubicin

lymphoma

rituximab

0 views
19 Feb, 2024
1 location

Phase 2
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Cardiovascular Diseases
Recruiting

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.

taxane

adjuvant chemotherapy

cancer

breast cancer

residual tumor

0 views
19 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2026 All rights reserved.